Sartorius AG (DE:SRT)
XETRA:SRT
Want to see DE:SRT full AI Analyst Report?
SRT Stock Chart & Stats
€194.40
€1.00(0.53%)
At close: 4:00 PM EST
€194.40
€1.00(0.53%)
Day’s Range― - ―
52-Week Range€145.40 - €208.00
Previous CloseN/A
Volume213.00
Average Volume (3M)5.04K
Market Cap
€13.54B
Enterprise Value€18.72B
Total Cash (Recent Filing)€573.80M
Total Debt (Recent Filing)€4.30B
Price to Earnings (P/E)65.1
Beta1.31
Next Earnings
Jul 16, 2026EPS Estimate
1.38Next Dividend Ex-DateN/A
Dividend Yield0.39%
Share Statistics
EPS (TTM)2.35
Shares Outstanding37,440,000
10 Day Avg. Volume4,524
30 Day Avg. Volume5,035
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)6.31
Price to Sales (P/S)4.82
P/FCF Ratio79.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€246.00Price Target Upside26.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)5.42
Revenue Forecast (FY)€3.75B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables / Installed BaseMid‑teens recurring consumables growth signals durable, repeatable revenue from an installed base. This creates predictable demand that supports margins, cash flow and customer stickiness over multiple quarters, reducing reliance on cyclical equipment sales for revenue stability.
Bioprocess Solutions OutperformanceBPS is the higher‑margin, faster‑growing core of the business. Strong top‑line and margin expansion in BPS reflects structural demand for bioprocess consumables and systems, boosting group profitability resilience and providing a reliable growth engine over the medium term.
Strategic Innovation, M&A And Capacity ExpansionNew product platforms, targeted M&A and capacity build‑outs expand the addressable market and embed the company deeper into customer workflows. These structural moves enhance long‑term competitiveness, support consumable demand and improve future revenue mix and scalability.
Bears Say
Elevated Leverage At Group LevelDespite deleveraging progress, leverage near mid‑single digits of EBITDA limits financial flexibility. Elevated net debt increases vulnerability to margin or demand shocks, constrains reinvestment or M&A optionality and elongates the timeline to normalize capital structure under weaker earnings.
Compressed Profitability Vs Prior CycleMaterial margin compression versus prior cycles implies lower earnings quality and reduced ability to convert revenue into durable free cash flow. Sustained lower margins limit deleveraging pace and make the company more sensitive to cost inflation, FX and tariff pressures over time.
Equipment Demand Softness And Uncertain RecoveryProlonged weakness in capital equipment reduces visibility for higher‑ticket sales that seed future consumables and typically carry stronger margins. Uncertain timing for equipment recovery makes revenue and margin normalization dependent on unpredictable capex cycles and on‑shoring dynamics.
Sartorius News
SRT FAQ
What was Sartorius AG’s price range in the past 12 months?
Sartorius AG lowest stock price was €145.40 and its highest was €208.00 in the past 12 months.
What is Sartorius AG’s market cap?
Sartorius AG’s market cap is €13.54B.
When is Sartorius AG’s upcoming earnings report date?
Sartorius AG’s upcoming earnings report date is Jul 16, 2026 which is in 72 days.
How were Sartorius AG’s earnings last quarter?
Sartorius AG released its earnings results on Apr 23, 2026. The company reported €1.2 earnings per share for the quarter, missing the consensus estimate of €1.284 by -€0.084.
Is Sartorius AG overvalued?
According to Wall Street analysts Sartorius AG’s price is currently Undervalued.
Does Sartorius AG pay dividends?
Sartorius AG pays a Annually dividend of €0.73 which represents an annual dividend yield of 0.39%. See more information on Sartorius AG dividends here
What is Sartorius AG’s EPS estimate?
Sartorius AG’s EPS estimate is 1.38.
How many shares outstanding does Sartorius AG have?
Sartorius AG has 37,440,000 shares outstanding.
What happened to Sartorius AG’s price movement after its last earnings report?
Sartorius AG reported an EPS of €1.2 in its last earnings report, missing expectations of €1.284. Following the earnings report the stock price went down -10.345%.
Which hedge fund is a major shareholder of Sartorius AG?
Currently, no hedge funds are holding shares in DE:SRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sartorius Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€246.00 (26.54% Upside)
€246.00 (26.54% Upside)
Insider Transactions
Bought Shares
Worth €286.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.06%
12-Months-Change
Fundamentals
Return on Equity
6.05%
Trailing 12-Months
Asset Growth
-2.38%
Trailing 12-Months
Company Description
Sartorius AG
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.
SRT Stock 12 Month Forecast
Average Price Target
€246.00
▲(26.54% Upside)
Technical Analysis
Evonik
―
GEA Group AG
―
Gerresheimer
―
Pfeiffer Vacuum Technology
―
STRATEC Biomedical
―
Options Prices
Currently, No data available
---